Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital

Table 1 HCC patient characteristics

Patient characters		n	%	Mean	Range
Age (years)	All			54.4	20-89
	Male			54.3	20-89
	Female			55.0	20-81
Sex	Male	276	82.0
	Female	60	18.0
Risk factors	Alcohol drinking	126	38.0
	HBsAg positive (299 sample)	217	72.6
	anti-HCV positive (135 sample)	10	7.4
	Cirrhosis	219	65.2
Liver function test	Total bilirubin (μmol·L-1)			63.8	3.4-752.4
	Direct bilirubin (μmol·L-1)			38.8	0.5-581.4
	Aspatate aminotransferase (U·L-1)			225	17-3890
	Alanine aminotransferase (U·L-1)			97	4-3370
	Alkaline phosphatase (U·L-1)			304	8-2080
	Albumin (g·L-1)			35.6	20-52
	Globulin (g·L-1)			38.2	18-78
Radiologic finding	Solitary type (total)	240	73.0
(n = 329)	with daughter nodules	144	43.8
	without daughter nodules	96	29.2
	Multinodular type	47	14.3
	Diffuse or infiltrative type	42	12.7
Alpha fetoprotein (μg·L-1) (n = 295)					1451102-7990000
	< 10	38	13.0
	10-99	36	12.0
	100-499	33	11.0
	≥ 500	188	64.0
Okuda's staging	Stage I	51	15.0
	Stage II	205	61.0
	Stage III	80	24.0

Table 2 Presenting symptoms and abnormal physical findings of patients

Presenting symptoms	n	%
Mass-related symptoms (Abdominal pain or fullness, dyspepsia, palpable mass)	188	56
Cirrhosis-related symptoms (Jaundice, GI bleeding, edema, abdominal enlargement, encephalopathy)	59	17.6
Liver abscess-like symptoms (High fever with acute abdominal pain and tenderness)	45	13.4
Non-specific symptoms (Anorexia, nausea, vomiting, malaise, weight loss, chronic anemia)	26	7.7
Metastasis symptoms (Dyspnea, cough, bone pain, palpable lymph node)	11	3.2
Asymptomatic (Routine checked up or other unrelated disease)	7	2.1
Abnormal physical findings
Hepatomegaly	282	83.9
Fever	185	50.5
Jaundice	143	42.6
Anemia	138	41.1
Ascites	123	36.6
Cachexia	86	25.6
Chronic liver stigmata	86	25.6
Edema	59	17.6
Splenomegaly	42	12.5

Table 3 Median survival

Group of patients	n	Median survival (months)
All	336	2.1
Stage I	51	11.5
Stage II	205	2.6
Stage III	80	0.73
Untreated	245	1.6
Stage I	26	7.7
Stage II	146	1.8
Stage III	73	0.63
Treated	91	5.5
Stage I	25	13.7
Stage II	59	4.2
Stage III	7	1.7
TOCE	44	6.3
Stage I	11	24.3
Stage II	29	5.5
Stage III	4	1.4
Chemotherapy (adriamycin and/or 5-FU)	16	5.2
Multimodality therapy	12	17.1
(PIAF/iv, chemotherapy ± TOCE ± PEI)
Tamoxifen	9	3.0
PIAF regimen chemotherapy	5	*
Hepatectomy	4	$
PEI	1	$

^*Data of PIAF regimen chemotherapy is not completely finished. $It were too small number of patients to evaluated.